Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia

Background: Whether to continue renin–angiotensin–aldosterone system inhibitor (RAASi) therapy in patients with hyperkalemia remains a clinical challenge, particularly in patients with heart failure (HF), where RAASis remain the cornerstone of treatment. We investigated the incidence of dose reducti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohsaka, Shun, Okami, Suguru, Morita, Naru, Yajima, Toshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572691/
https://www.ncbi.nlm.nih.gov/pubmed/36233692
http://dx.doi.org/10.3390/jcm11195828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572691/
https://www.ncbi.nlm.nih.gov/pubmed/36233692
http://dx.doi.org/10.3390/jcm11195828

Ejemplares similares